Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Oregon Health & Science University at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Oregon Health & Science University brings 22 presentations to ASH 2026 in New Orleans. Its program centres on acute myeloid leukemia and systemic mastocytosis, including new targeted drugs. It covers a phase 1 study of the MALT1 inhibitor SGR-1505 and a triplet of iadademstat, azacitidine and venetoclax.

OrganizationASH 2026 Attendance
Universities & research institutes
Oregon's public academic health center, combining schools of medicine and nursing, hospitals and research institutes.
Session
Sat Dec 12
4:00pm–5:35pm
JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy
How RNA regulation, from splicing to RNA-binding proteins, shapes healthy blood formation and myeloid cancers, and how it could point to new treatments.
Blood biology · Leukemias

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Oregon Health & Science University

Tell us what you sell and we’ll find the people at Oregon Health & Science University most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction